Search

Your search keyword '"Goergen, Helen"' showing total 179 results
Start Over Author "Goergen, Helen"
179 results on '"Goergen, Helen"'

1. Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group

Author

Damaschin, Carla, Goergen, Helen, Kreissl, Stefanie, Plütschow, Annette, Breywisch, Frank, Mathas, Stephan, Meissner, Julia, Sökler, Martin, Topp, Max S., Vucinic, Vladan, Zimmermann, Andreas, von Tresckow, Bastian, Fuchs, Michael, Engert, Andreas, Borchmann, Peter, and Eichenauer, Dennis A.

Published
2022
Full Text
View/download PDF

3. PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial

Author

Kreissl, Stefanie, Goergen, Helen, Buehnen, Ina, Kobe, Carsten, Moccia, Alden, Greil, Richard, Eichenauer, Dennis A, Zijlstra, Josée M, Markova, Jana, Meissner, Julia, Feuring-Buske, Michaela, Soekler, Martin, Beck, Hans-Joachim, Willenbacher, Wolfgang, Ludwig, Wolf-Dieter, Pabst, Thomas, Topp, Max S, Hitz, Felicitas, Bentz, Martin, Keller, Ulrich Bernd, Kühnhardt, Dagmar, Ostermann, Helmut, Hertenstein, Bernd, Aulitzky, Walter, Maschmeyer, Georg, Vieler, Tom, Eich, Hans, Baues, Christian, Stein, Harald, Fuchs, Michael, Diehl, Volker, Dietlein, Markus, Engert, Andreas, and Borchmann, Peter

Published
2021
Full Text
View/download PDF

6. PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group

Author

Borchmann, Peter, Goergen, Helen, Kobe, Carsten, Lohri, Andreas, Greil, Richard, Eichenauer, Dennis A, Zijlstra, Josée M, Markova, Jana, Meissner, Julia, Feuring-Buske, Michaela, Hüttmann, Andreas, Dierlamm, Judith, Soekler, Martin, Beck, Hans-Joachim, Willenbacher, Wolfgang, Ludwig, Wolf-Dieter, Pabst, Thomas, Topp, Max S, Hitz, Felicitas, Bentz, Martin, Keller, Ulrich Bernd, Kühnhardt, Dagmar, Ostermann, Helmut, Schmitz, Norbert, Hertenstein, Bernd, Aulitzky, Walter, Maschmeyer, Georg, Vieler, Tom, Eich, Hans, Baues, Christian, Stein, Harald, Fuchs, Michael, Kuhnert, Georg, Diehl, Volker, Dietlein, Markus, and Engert, Andreas

Published
2017
Full Text
View/download PDF

8. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial

Author

Behringer, Karolin, Goergen, Helen, Hitz, Felicitas, Zijlstra, Josée M, Greil, Richard, Markova, Jana, Sasse, Stephanie, Fuchs, Michael, Topp, Max S, Soekler, Martin, Mathas, Stephan, Meissner, Julia, Wilhelm, Martin, Koch, Peter, Lindemann, Hans-Walter, Schalk, Enrico, Semrau, Robert, Kriz, Jan, Vieler, Tom, Bentz, Martin, Lange, Elisabeth, Mahlberg, Rolf, Hassler, Andre, Vogelhuber, Martin, Hahn, Dennis, Mezger, Jörg, Krause, Stefan W, Skoetz, Nicole, Böll, Boris, von Tresckow, Bastian, Diehl, Volker, Hallek, Michael, Borchmann, Peter, Stein, Harald, Eich, Hans, and Engert, Andreas

Published
2015
Full Text
View/download PDF

9. 9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial

Author

Gerhard‐Hartmann, Elena, primary, Goergen, Helen, additional, Bröckelmann, Paul J., additional, Mottok, Anja, additional, Steinmüller, Tabea, additional, Grund, Johanna, additional, Zamò, Alberto, additional, Ben‐Neriah, Susana, additional, Sasse, Stephanie, additional, Borchmann, Sven, additional, Fuchs, Michael, additional, Borchmann, Peter, additional, Reinke, Sarah, additional, Engert, Andreas, additional, Veldman, Johanna, additional, Diepstra, Arjan, additional, Klapper, Wolfram, additional, and Rosenwald, Andreas, additional

Published
2021
Full Text
View/download PDF

10. Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group

Author

Damaschin, Carla, primary, Goergen, Helen, additional, Kreissl, Stefanie, additional, Plütschow, Annette, additional, Breywisch, Frank, additional, Mathas, Stephan, additional, Meissner, Julia, additional, Sökler, Martin, additional, Topp, Max S., additional, Vucinic, Vladan, additional, Zimmermann, Andreas, additional, von Tresckow, Bastian, additional, Fuchs, Michael, additional, Engert, Andreas, additional, Borchmann, Peter, additional, and Eichenauer, Dennis A., additional

Published
2021
Full Text
View/download PDF

11. Histopathological growth patterns in patients with advanced nodular lymphocyte‐predominant Hodgkin lymphoma treated within the randomized HD18 study: a report from the German Hodgkin Study Group

Author

Eichenauer, Dennis A., primary, Bühnen, Ina, additional, Kreissl, Stefanie, additional, Goergen, Helen, additional, Fuchs, Michael, additional, Tresckow, Bastian, additional, Rosenwald, Andreas, additional, Klapper, Wolfram, additional, Hansmann, Martin‐Leo, additional, Möller, Peter, additional, Bernd, Heinz‐Wolfram, additional, Feller, Alfred C., additional, Engert, Andreas, additional, Borchmann, Peter, additional, and Hartmann, Sylvia, additional

Published
2021
Full Text
View/download PDF

12. Impact of centralized diagnostic review on quality of initial staging in Hodgkin lymphoma: experience of the German Hodgkin Study Group

Author

Bröckelmann, Paul J., Goergen, Helen, Fuchs, Michael, Kriz, Jan, Semrau, Robert, Baues, Christian, Kobe, Carsten, Behringer, Karolin, Eichenauer, Dennis A., von Tresckow, Bastian, Klimm, Beate, Halbsguth, Teresa, Wongso, Diana, Plütschow, Annette, Haverkamp, Heinz, Dietlein, Markus, Eich, Hans T., Stein, Harald, Diehl, Volker, Borchmann, Peter, and Engert, Andreas

Published
2015
Full Text
View/download PDF

14. Early Response to First-Line Anti–PD-1 Treatment in Hodgkin Lymphoma: A PET-Based Analysis from the Prospective, Randomized Phase II NIVAHL Trial

Author

Voltin, Conrad-Amadeus, primary, Mettler, Jasmin, additional, van Heek, Lutz, additional, Goergen, Helen, additional, Müller, Horst, additional, Baues, Christian, additional, Keller, Ulrich, additional, Meissner, Julia, additional, Trautmann-Grill, Karolin, additional, Kerkhoff, Andrea, additional, Fuchs, Michael, additional, Sasse, Stephanie, additional, von Tresckow, Bastian, additional, Dietlein, Markus, additional, Borchmann, Peter, additional, Engert, Andreas, additional, Kobe, Carsten, additional, and Bröckelmann, Paul J., additional

Published
2021
Full Text
View/download PDF

15. Efficacy and Safety of Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Extended Follow-up from the GHSG Phase II Nivahl Trial

Author

Bröckelmann, Paul J, primary, Goergen, Helen, additional, Keller, Ulrich, additional, Meissner, Julia, additional, Trautmann, Karolin, additional, Halbsguth, Teresa V, additional, Sasse, Stephanie, additional, Sökler, Martin, additional, Kerkhoff, Andrea, additional, Mathas, Stephan, additional, Hüttmann, Andreas, additional, Bormann, Matthias, additional, Zimmermann, Andreas, additional, Fuchs, Michael, additional, von Tresckow, Bastian, additional, Baues, Christian, additional, Rosenwald, Andreas, additional, Klapper, Wolfram, additional, Kobe, Carsten, additional, Borchmann, Peter, additional, and Engert, Andreas, additional

Published
2020
Full Text
View/download PDF

17. Health-Related Quality of Life in Patients With Hodgkin Lymphoma: A Longitudinal Analysis of the German Hodgkin Study Group

Author

Kreissl, Stefanie, primary, Müller, Horst, additional, Goergen, Helen, additional, Meissner, Julia, additional, Topp, Max, additional, Sökler, Martin, additional, Markova, Jana, additional, Bernhard, Jürg, additional, Greil, Richard, additional, von Tresckow, Bastian, additional, Behringer, Karolin, additional, Rüffer, Jens-Ulrich, additional, Flechtner, Hans-Henning, additional, Möstl, Michaela, additional, Fuchs, Michael, additional, Engert, Andreas, additional, Diehl, Volker, additional, and Borchmann, Peter, additional

Published
2020
Full Text
View/download PDF

18. 9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial.

Author

Gerhard‐Hartmann, Elena, Goergen, Helen, Bröckelmann, Paul J., Mottok, Anja, Steinmüller, Tabea, Grund, Johanna, Zamò, Alberto, Ben‐Neriah, Susana, Sasse, Stephanie, Borchmann, Sven, Fuchs, Michael, Borchmann, Peter, Reinke, Sarah, Engert, Andreas, Veldman, Johanna, Diepstra, Arjan, Klapper, Wolfram, and Rosenwald, Andreas

Subjects
*PROGRAMMED death-ligand 1, *HODGKIN'S disease, *MANTLE cell lymphoma, *MAJOR histocompatibility complex
Abstract

Summary: High programmed cell death 1 ligand 1 (PD‐L1) protein expression and copy number alterations (CNAs) of the corresponding genomic locus 9p24.1 in Hodgkin‐ and Reed–Sternberg cells (HRSC) have been shown to be associated with favourable response to anti‐PD‐1 checkpoint inhibition in relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL). In the present study, we investigated baseline 9p24.1 status as well as PD‐L1 and major histocompatibility complex (MHC) class I and II protein expression in 82 biopsies from patients with early stage unfavourable cHL treated with anti‐PD‐1‐based first‐line treatment in the German Hodgkin Study Group (GHSG) NIVAHL trial (ClinicalTrials.gov Identifier: NCT03004833). All evaluated specimens showed 9p24.1 CNA in HRSC to some extent, but with high intratumoral heterogeneity and an overall smaller range of alterations than reported in advanced‐stage or r/r cHL. All but two cases (97%) showed PD‐L1 expression by the tumour cells in variable amounts. While MHC‐I was rarely expressed in >50% of HRSC, MHC‐II expression in >50% of HRSC was found more frequently. No obvious impact of 9p24.1 CNA or PD‐L1 and MHC‐I/II expression on early response to the highly effective anti‐PD‐1‐based NIVAHL first‐line treatment was observed. Further studies evaluating an expanded panel of potential biomarkers are needed to optimally stratify anti‐PD‐1 first‐line cHL treatment. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

19. Histopathological growth patterns in patients with advanced nodular lymphocyte‐predominant Hodgkin lymphoma treated within the randomized HD18 study: a report from the German Hodgkin Study Group.

Author

Eichenauer, Dennis A., Bühnen, Ina, Kreissl, Stefanie, Goergen, Helen, Fuchs, Michael, von Tresckow, Bastian, Rosenwald, Andreas, Klapper, Wolfram, Hansmann, Martin‐Leo, Möller, Peter, Bernd, Heinz‐Wolfram, Feller, Alfred C., Engert, Andreas, Borchmann, Peter, and Hartmann, Sylvia

Subjects
HODGKIN'S disease, POSITRON emission tomography, HISTOPATHOLOGY, PROGRESSION-free survival, OVERALL survival, NEUROECTODERMAL tumors
Abstract

Summary: We retrospectively investigated histopathological growth patterns in individuals with advanced nodular lymphocyte‐predominant Hodgkin lymphoma (NLPHL) treated within the randomized HD18 study. In all, 35/60 patients (58%) presented with atypical growth patterns. Patients with atypical growth patterns more often had stage IV disease (P = 0·0354) and splenic involvement (P = 0·0048) than patients with typical growth patterns; a positive positron emission tomography after two cycles of chemotherapy (PET‐2) tended to be more common (P = 0·1078). Five‐year progression‐free survival [hazard ratio (HR) = 0·86; 95% confidence interval (CI) = 0·49–1·47] and overall survival (HR = 0·85; 95% CI = 0·49–1·51) did not differ between the groups after study treatment with PET‐2‐guided escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone). Thus, advanced NLPHL is often associated with atypical growth patterns but their prognostic impact is compensated by PET‐2‐guided escalated BEACOPP. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

20. Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma

Author

Bröckelmann, Paul J., primary, Goergen, Helen, additional, Keller, Ulrich, additional, Meissner, Julia, additional, Ordemann, Rainer, additional, Halbsguth, Teresa V., additional, Sasse, Stephanie, additional, Sökler, Martin, additional, Kerkhoff, Andrea, additional, Mathas, Stephan, additional, Hüttmann, Andreas, additional, Bormann, Matthias, additional, Zimmermann, Andreas, additional, Mettler, Jasmin, additional, Fuchs, Michael, additional, von Tresckow, Bastian, additional, Baues, Christian, additional, Rosenwald, Andreas, additional, Klapper, Wolfram, additional, Kobe, Carsten, additional, Borchmann, Peter, additional, and Engert, Andreas, additional

Published
2020
Full Text
View/download PDF

21. Reply to H.J.A. Adams et al

Author

Fuchs, Michael, primary, Goergen, Helen, additional, Kobe, Carsten, additional, Borchmann, Peter, additional, and Engert, Andreas, additional

Published
2020
Full Text
View/download PDF

22. Pretreatment Vitamin D Deficiency Is Associated With Impaired Progression-Free and Overall Survival in Hodgkin Lymphoma

Author

Borchmann, Sven, primary, Cirillo, Melita, additional, Goergen, Helen, additional, Meder, Lydia, additional, Sasse, Stephanie, additional, Kreissl, Stefanie, additional, Bröckelmann, Paul Jan, additional, von Tresckow, Bastian, additional, Fuchs, Michael, additional, Ullrich, Roland Tillmann, additional, and Engert, Andreas, additional

Published
2019
Full Text
View/download PDF

24. Nivolumab and AVD for Early-Stage Unfavorable Hodgkin Lymphoma (NIVAHL)

Author

Bröckelmann, Paul J, primary, Goergen, Helen, primary, Keller, Ulrich, primary, Meissner, Julia, primary, Ordemann, Rainer, primary, Halbsguth, Teresa V, primary, Sasse, Stephanie, primary, Sökler, Martin, primary, Kerkhoff, Andrea, primary, Mathas, Stephan, primary, Hüttmann, Andreas, primary, Bormann, Matthias, primary, Zimmermann, Andreas, primary, Fuchs, Michael, primary, von Tresckow, Bastian, primary, Baues, Christian, primary, Rosenwald, Andreas, primary, Klapper, Wolfram, primary, Kobe, Carsten, primary, Borchmann, Peter, primary, and Engert, Andreas, primary

Published
2019
Full Text
View/download PDF

25. Positron Emission Tomography–Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group

Author

Fuchs, Michael, primary, Goergen, Helen, additional, Kobe, Carsten, additional, Kuhnert, Georg, additional, Lohri, Andreas, additional, Greil, Richard, additional, Sasse, Stephanie, additional, Topp, Max S., additional, Schäfer, Erhardt, additional, Hertenstein, Bernd, additional, Soekler, Martin, additional, Vogelhuber, Martin, additional, Zijlstra, Josée M., additional, Keller, Ulrich Bernd, additional, Krause, Stefan W., additional, Wilhelm, Martin, additional, Maschmeyer, Georg, additional, Thiemer, Julia, additional, Dührsen, Ulrich, additional, Meissner, Julia, additional, Viardot, Andreas, additional, Eich, Hans, additional, Baues, Christian, additional, Diehl, Volker, additional, Rosenwald, Andreas, additional, von Tresckow, Bastian, additional, Dietlein, Markus, additional, Borchmann, Peter, additional, and Engert, Andreas, additional

Published
2019
Full Text
View/download PDF

29. Reduced-Intensity Chemotherapy in Patients With Advanced-Stage Hodgkin Lymphoma

Author

Engert, Andreas, Goergen, Helen, Markova, Jana, Pabst, Thomas, Meissner, Julia, Zijlstra, Josée M., Král, Zdenek, Eichenauer, Dennis A., Soekler, Martin, Greil, Richard, Kreissl, Stefanie, Scheuvens, Ruth, Eich, Hans, Kobe, Carsten, Dietlein, Markus, Stein, Harald, Fuchs, Michael, Diehl, Volker, and Borchmann, Peter

Subjects
long-term outcome, lcsh:RC633-647.5, Original Article, Advanced stages, lcsh:Diseases of the blood and blood-forming organs, Hodgkin lymphoma
Abstract

The international, randomized phase 3 HD15 trial established 6xeBEACOPP as standard therapy for patients with newly diagnosed advanced-stage Hodgkin lymphoma (HL) within the German Hodgkin Study Group (GHSG). We performed a follow-up analysis to assess long-term efficacy and safety of this approach. Between 2003 and 2008, 2182 patients aged 18 to 60 years were recruited and randomized in a 1:1:1 ratio between 8 or 6 cycles of eBEACOPP or 8 cycles of the dose-dense BEACOPP-14 regimen, each followed by 30 Gy radiotherapy in case of positron emission tomography (PET)-positive residual lesions ≥2.5 cm. The study aimed at demonstrating non-inferiority regarding efficacy of the 2 experimental arms on a significance level of 2.5% each. The intention-to-treat analysis comprised 2126 patients with a median follow-up of 102 months. Ten-year progression-free survival was 81% (97.5% CI 77–85) with 8xeBEACOPP, 84% (80–87) with 6xeBEACOPP, and 84% (80–87) with 8xBEACOPP-14; the non-inferiority margin of 1.51 for the hazard ratio (HR) could be excluded for both comparisons (6xeBEACOPP, HR = 0.7, 97.5% CI 0.5–1.0; 8xBEACOPP-14, HR = 0.9, 97.5% CI 0.7–1.2). Overall survival at 10 years was 88% (85–91), 90% (88–93), and 92% (89–94), respectively. A total of 142 second malignancies corresponding to 10-year cumulative incidences of 10%, 7%, and 7% and standardized incidence ratios of 4.3, 2.5, and 2.8 were reported for 8xeBEACOPP, 6xeBEACOPP, and 8xBEACOPP-14, respectively. This updated analysis of the HD15 trial thus confirms the efficacy and reports on the long-term safety of a shortened first-line chemotherapy consisting of 6xeBEACOPP followed by PET-guided radiotherapy in advanced-stage HL.

Published
2017

31. PET-Guided Treatment of Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase 3 Trial HD16 By the German Hodgkin Study Group

Author

Fuchs, Michael, primary, Goergen, Helen, additional, Kobe, Carsten, additional, Eich, Hans, additional, Baues, Christian, additional, Greil, Richard, additional, Sasse, Stephanie, additional, Zijlstra, Josée M, additional, Lohri, Andreas, additional, Rosenwald, Andreas, additional, von Tresckow, Bastian, additional, Diehl, Volker, additional, Kuhnert, Georg, additional, Dietlein, Markus, additional, Borchmann, Peter, additional, and Engert, Andreas, additional

Published
2018
Full Text
View/download PDF

32. B-CAP (brentuximab vedotin, cyclophosphamide, doxorubicin and predniso(lo)Ne) in Older Patients with Advanced-Stage Hodgkin Lymphoma: Results of a Phase II Intergroup Trial By the German Hodgkin Study Group (GHSG) and the Nordic Lymphoma Group (NLG)

Author

Boell, Boris, primary, Fosså, Alexander, additional, Goergen, Helen, additional, Kamper, Peter, additional, Leppa, Sirpa, additional, Molin, Daniel, additional, Meissner, Julia, additional, Ritter, Ellen, additional, Christensen, Jacob H., additional, Hutchings, Martin, additional, Fuchs, Michael, additional, Engert, Andreas, additional, Kobe, Carsten, additional, and Borchmann, Peter, additional

Published
2018
Full Text
View/download PDF

33. Outcome of Patients With Early-Stage Infradiaphragmatic Hodgkin Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group

Author

Sasse, Stephanie, primary, Goergen, Helen, additional, Plütschow, Annette, additional, Böll, Boris, additional, Eichenauer, Dennis A., additional, Fuchs, Michael, additional, Behringer, Karolin, additional, Zijlstra, Joseé M., additional, Greil, Richard, additional, Markova, Jana, additional, Topp, Max S., additional, Meissner, Julia, additional, Neubauer, Andreas, additional, Baues, Christian, additional, Engert, Andreas, additional, Borchmann, Peter, additional, and von Tresckow, Bastian, additional

Published
2018
Full Text
View/download PDF

37. Early Interim PET in Patients with Advanced-Stage Hodgkin's Lymphoma Treated within the Phase 3 GHSG HD18 Study

Author

Borchmann, Peter, primary, Goergen, Helen, additional, Kobe, Carsten, additional, Lohri, Andreas, additional, Greil, Richard, additional, Eichenauer, Dennis A., additional, Zijlstra, Josée M, additional, Markova, Jana, additional, Meissner, Julia, additional, Feuring-Buske, Michaela, additional, Hüttmann, Andreas, additional, Dierlamm, Judith, additional, Sökler, Martin, additional, Krause, Stefan W., additional, Eich, Hans, additional, Baues, Christian, additional, Kreissl, Stefanie, additional, Fuchs, Michael, additional, Dietlein, Markus, additional, and Engert, Andreas, additional

Published
2017
Full Text
View/download PDF

38. Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials

Author

Sasse, Stephanie, primary, Bröckelmann, Paul J., additional, Goergen, Helen, additional, Plütschow, Annette, additional, Müller, Horst, additional, Kreissl, Stefanie, additional, Buerkle, Carolin, additional, Borchmann, Sven, additional, Fuchs, Michael, additional, Borchmann, Peter, additional, Diehl, Volker, additional, and Engert, Andreas, additional

Published
2017
Full Text
View/download PDF

39. Late Relapse of Classical Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group HD7 to HD12 Trials

Author

Bröckelmann, Paul J., primary, Goergen, Helen, additional, Kohnhorst, Charlotte, additional, von Tresckow, Bastian, additional, Moccia, Alden, additional, Markova, Jana, additional, Meissner, Julia, additional, Kerkhoff, Andrea, additional, Ludwig, Wolf-Dieter, additional, Fuchs, Michael, additional, Borchmann, Peter, additional, and Engert, Andreas, additional

Published
2017
Full Text
View/download PDF

40. Cancer-Related Fatigue in Patients With and Survivors of Hodgkin Lymphoma: The Impact on Treatment Outcome and Social Reintegration

Author

Behringer, Karolin, primary, Goergen, Helen, additional, Müller, Horst, additional, Thielen, Indra, additional, Brillant, Corinne, additional, Kreissl, Stefanie, additional, Halbsguth, Teresa Veronika, additional, Meissner, Julia, additional, Greil, Richard, additional, Moosmann, Peter, additional, Shonukan, Oluwatoyin, additional, Rueffer, Jens Ulrich, additional, Flechtner, Hans-Henning, additional, Fuchs, Michael, additional, Diehl, Volker, additional, Engert, Andreas, additional, and Borchmann, Peter, additional

Published
2016
Full Text
View/download PDF

42. Survivors' perspectives on risks and benefits of Hodgkin lymphoma treatment: results of a survey by the German Hodgkin Study Group.

Author

Kreissl, Stefanie, Goergen, Helen, Müller, Horst, Bürkle, Carolin, Fuchs, Michael, Engert, Andreas, Behringer, Karolin, Borchmann, Peter, Meissner, Julia, and Mehnert, Anja

Subjects
*HODGKIN'S disease, *LYMPHOMA treatment, *THERAPEUTICS, *FOLLOW-up studies (Medicine)
Abstract

We performed a survey in Hodgkin lymphoma survivors to learn more about their perspectives on treatment risks and benefits. We sent questions to 1149 survivors from the GHSG's HD13-15 trials with (N = 249) or without (N =900) documented progression or relapse. The participation rate was 52% (N =581). After median follow-up of 106 months, 40% of relapse-free and over 60% of relapsed survivors were still worried about late effects and the possibility of relapse. Chemotherapy, largely independent of its intensity, had been a strain on 74% of relapse-free and 90% of relapsed survivors. Most physical, psychological, and socio-economic sequelae were more frequent among relapsed survivors (p <.05) and described as very burdensome. 74% of relapse-free and 61% of relapsed survivors considered primary cure from Hodgkin lymphoma as the most important aspect in the choice of treatment. Accordingly, primary optimal lymphoma control is of utmost importance from the patients' perspective. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

43. Primary Progressive Disease in Hodgkin Lymphoma Patients: A Retrospective Analysis from the German Hodgkin Study Group

Author

Kreissl, Stefanie, primary, Goergen, Helen, additional, von Tresckow, Bastian, additional, Behringer, Karolin, additional, Markova, Jana, additional, Lohri, Andreas, additional, Meissner, Julia, additional, Zijlstra, Josée M, additional, Greil, Richard, additional, Topp, Max S., additional, Sökler, Martin, additional, Döhner, Hartmut, additional, Diehl, Volker, additional, Engert, Andreas, additional, and Borchmann, Peter, additional

Published
2015
Full Text
View/download PDF

44. Phase II Study of Ofatumumab in Relapsed Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report from the German Hodgkin Study Group

Author

Eichenauer, Dennis A., primary, Goergen, Helen, additional, Pluetschow, Annette, additional, Behringer, Karolin, additional, Kreissl, Stefanie, additional, Bröckelmann, Paul, additional, Fuchs, Michael, additional, Böll, Boris, additional, von Tresckow, Bastian, additional, Borchmann, Peter, additional, and Engert, Andreas, additional

Published
2015
Full Text
View/download PDF

46. Relapsed Hodgkin Lymphoma in Older Patients: A Comprehensive Analysis From the German Hodgkin Study Group

Author

Böll, Boris, primary, Goergen, Helen, additional, Arndt, Nils, additional, Meissner, Julia, additional, Krause, Stefan W., additional, Schnell, Roland, additional, von Tresckow, Bastian, additional, Eichenauer, Dennis A., additional, Sasse, Stephanie, additional, Fuchs, Michael, additional, Behringer, Karolin, additional, Klimm, Beate C., additional, Naumann, Ralph, additional, Diehl, Volker, additional, Engert, Andreas, additional, and Borchmann, Peter, additional

Published
2013
Full Text
View/download PDF

47. Brentuximab vedotin (SGN-35) in patients with transplant-naive relapsed/refractory Hodgkin lymphoma

Author

Sasse, Stephanie, primary, Rothe, Achim, additional, Goergen, Helen, additional, Eichenauer, Dennis A., additional, Lohri, Andreas, additional, Kreher, Stephan, additional, Jäger, Ulrich, additional, Bangard, Christopher, additional, Kuhnert, Georg, additional, Böll, Boris, additional, von Tresckow, Bastian, additional, and Engert, Andreas, additional

Published
2013
Full Text
View/download PDF

48. Gonadal Function and Fertility in Survivors After Hodgkin Lymphoma Treatment Within the German Hodgkin Study Group HD13 to HD15 Trials

Author

Behringer, Karolin, primary, Mueller, Horst, additional, Goergen, Helen, additional, Thielen, Indra, additional, Eibl, Angelika Diana, additional, Stumpf, Volker, additional, Wessels, Carsten, additional, Wiehlpütz, Martin, additional, Rosenbrock, Johannes, additional, Halbsguth, Teresa, additional, Reiners, Katrin S., additional, Schober, Thomas, additional, Renno, Jorg H., additional, von Wolff, Michael, additional, van der Ven, Katrin, additional, Kuehr, Marietta, additional, Fuchs, Michael, additional, Diehl, Volker, additional, Engert, Andreas, additional, and Borchmann, Peter, additional

Published
2013
Full Text
View/download PDF

50. Treatment of Stage I-II A Non-Bulky Hodgkin's Lymphoma (HL): An Individual Patient-Data Comparison of German Hodgkin Study Group (GHSG) HD10 and HD11 Combined-Modality Therapy (CMT) and NCIC Clinical Trials Group (NCIC CTG) HD.6 ABVD Alone

Author

Hay, Annette E., primary, Klimm, Beate, additional, Chen, Bingshu E., additional, Goergen, Helen, additional, Shepherd, Lois E., additional, Fuchs, Michael, additional, Gospodarowicz, Mary, additional, Borchmann, Peter, additional, Connors, Joseph M., additional, Markova, Jana, additional, Crump, Michael, additional, Lohri, Andreas, additional, Winter, Jane N., additional, Dörken, Bernd, additional, Pearcey, Robert G., additional, Diehl, Volker, additional, Horning, Sandra J., additional, Eich, Hans Theodor, additional, Engert, Andreas, additional, and Meyer, Ralph M., additional

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results